Register today for our upcoming lunch seminar on Friday, April 18th, at Taverna in Palo Alto, CA from 11:30 a.m. to 1:00 p.m.

Event Details:

• Date/Location: Friday, April 18, 2025, at Taverna, 800 Emerson Street, Palo Alto, CA 94301
• Registration & Check-In: 11:30 am – 12 pm
• Presentation & Q&A with lunch included: 12:00 pm – 1 pm

Overview:

Biological candidates are often screened and selected based on activity and functionality, with less attention paid to other essential attributes such as manufacturability and immunogenicity. To overlook these key areas in the early stages of drug development can leave drug developers vulnerable, with a less-than-ideal candidate to progress onward toward the clinic.

Having a good all-around understanding of all your molecule’s characteristics is essential to ensure that only candidates with the best properties are progressed. This is where developability assessments come in.  Developability refers to the likelihood that a biologic or bioconjugate will become a manufacturable, safe, and efficacious drug. When employed effectively, it aims to increase the probability of a molecule successfully reaching regulatory approval.

Join our VP of Research& Innovation, Dr Rob Holgate, for a lunch seminar in Palo Alto, CA on Friday, April 18^th, to gain a better understanding of how advanced scientific methodologies, cutting-edge technology, and a deep understanding of biologics can be applied to deliver unparalleled developability solutions – so that you can move closer to developing ideal drugs.

What You’ll Learn:

• How these assessments can provide you with a greater understanding of your drug candidates before committing to preclinical development
• How developability assessment can save time and money by allowing scope for early risk mitigation or corrective engineering
• How these assessments can offer the highest chance of progressing a successful candidate to the clinic

Register Here:


Our Speaker:

Rob Holgate, Vice President of Research & Innovation

Rob Holgate, PhD studied at Kings College, London, where he obtained a First Class (Hons) degree in Biochemistry. After receiving his PhD in Molecular Medicine from The Institute of Child Health, part of University College London, he moved to the University of York as a postdoctoral researcher. Rob formally worked at Cambridge Antibody Technology, where he served as a Senior Scientist in Antibody Engineering and later as Team Leader of the High-Throughput Expression team.

Rob joined Antitope (now Abzena) in 2008 as a Research Manager and now leads Abzena’s Protein Engineering and Antibody Discovery groups, overseeing the company’s discovery, antibody humanization, protein deimmunization, and bespoke engineering projects.